Page last updated: 2024-12-07

farnesoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

farnesoic acid : A methyl-branched, trienoic fatty acid consisting of dodeca-2,6,10-trienoic acid having three methyl substituents at the 3-, 7- and 11-positions. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

(2E,6E)-farnesoic acid : A farnesoic acid in which the double bonds at positions 2 and 6 both have E-configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5275507
CHEMBL ID369779
CHEBI ID36969
CHEBI ID84162
SCHEMBL ID679567
MeSH IDM0051048

Synonyms (29)

Synonym
7548-13-2
CHEBI:36969
3,7,11-trimethyldodeca-2,6,10-trienoic acid
2,6,10-dodecatrienoic acid, 3,7,11-trimethyl-, (2e,6e)-
(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trienoic acid
trans,trans-farnesoic acid
farnesoic acid
462-11-3
(2e,6e)-farnesic acid
(2-trans-6-trans) farnesoic acid
all-trans-farnesoic acid
(2e,6e)-farnesenic acid
(e,e)-farnesoic acid
(2e,6e)-3,7,11-trimethyl-2,6,10-dodecatrienoic acid
(2e,6e)-farnesylic acid
(2e,6e)-farnesoic acid
2,6,10-dodecatrienoic acid, 3,7,11-trimethyl-
CHEMBL369779
chebi:84162 ,
98sid9vm1v ,
3,7,11-trimethyl-2,6,10-dodecatrienoic acid
SCHEMBL679567
(2e,6e)-3,7,11-trimethyl-2,6,10-dodecatrienoic acid #
WJHFZYAELPOJIV-IJFRVEDASA-N
3,7,11-trimethyl-dodeca-2,6,10-trienoic acid
Q27157527
Q27117003
(e,e)farnesoic acid, 95+% dry ice item
DTXSID901315326
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
animal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in animals that include diverse creatures from sponges, insects to mammals.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
farnesoic acidA methyl-branched, trienoic fatty acid consisting of dodeca-2,6,10-trienoic acid having three methyl substituents at the 3-, 7- and 11-positions.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID47224In vitro inhibition of yeast cell growth of candida albicans; No inhibition2002Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6
Evaluation of morphogenic regulatory activity of farnesoic acid and its derivatives against Candida albicans dimorphism.
AID47225In vitro inhibition of yeast-to-hypha transition in candida albicans2002Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6
Evaluation of morphogenic regulatory activity of farnesoic acid and its derivatives against Candida albicans dimorphism.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (52)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (7.69)18.7374
1990's8 (15.38)18.2507
2000's19 (36.54)29.6817
2010's21 (40.38)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other54 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]